Artificial Intelligence-Based Computer-Aided Diagnosis of Prostate Cancer

Launched by THE FIRST AFFILIATED HOSPITAL WITH NANJING MEDICAL UNIVERSITY · Aug 22, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how artificial intelligence (AI) can help doctors better diagnose prostate cancer using MRI scans. Prostate cancer is a significant health issue, with many men developing it during their lifetime. The current method for detecting prostate cancer through MRI can sometimes be inconsistent because it relies heavily on the expertise of the doctors interpreting the images. The trial aims to see if AI can improve the accuracy and reliability of these diagnoses, supporting doctors rather than replacing them.

To participate in this trial, men aged 60 and older who have signs that may indicate prostate cancer, such as high levels of a specific protein in the blood or unusual results from a physical exam, may be eligible. However, those who have had previous treatments for prostate cancer or certain imaging issues will not be included. Participants can expect to undergo MRI scans, and their results will be analyzed with the help of AI technology. This research is critical to understanding if AI can be a valuable tool in the fight against prostate cancer.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Clinical suspicious of prostate cancer, presenting with an elevated prostatic specific antigen and/or abnormal digital rectal examination
• Exclusion Criteria:
• • (1) \<60 years of age; (2) a previous surgery, radiotherapy or drug therapy for prostate cancer (interventions for benign prostatic hyperplasia or bladder outflow obstruction were deemed acceptable); (3) incomplete mp-MRI examination or artifacts of the images.